Lipid nanoparticles (LNPs) are rapidly becoming the cornerstone of clinical mRNA delivery,1,2 a status firmly established by the success of the Pfizer/BioNTech BNT162b2 and Moderna mRNA-1273 vaccines.3 These platforms validated the power of LNPs to protect fragile mRNA molecules and facilitate their efficient delivery into cells. However, the full therapeutic potential of mRNA technology, particularly for applications requiring repeated dosing such as cancer immunotherapy, is severely constrained by critical limitations of the standard polymer component, poly(ethylene glycol) (PEG).4 This article reviews the synthesis and comprehensive evaluation of next-generation PEG alternatives. The conclusions present an alternative in LNP engineering, demonstrating validated pathways to overcome the performance and safety bottlenecks of conventional formulations.
The Standard Four-Component LNP Architecture
Clinically validated LNPs use a four-component architecture, each with a distinct role: ionizable lipids (cationic at endosomal pH to encapsulate mRNA and drive its endosomal release), auxiliary phospholipids such as DSPC (bilayer stability), cholesterol (membrane fluidity and rigidity), and PEGylated lipids (a surface “stealth” coating that shields charge, prevents aggregation, and prolongs circulation). LNP behavior is highly sensitive to the molar ratios of these components, which govern nanostructure, surface charge, colloidal stability, and in vivo delivery. Stealth-polymer content is especially critical: lowering PEG can improve in vitro uptake by reducing steric hindrance, but too little PEG triggers rapid clearance in vivo by the mononuclear phagocyte system (MPS) — the trade-off that motivates the search for PEG alternatives.
The ‘PEG Dilemma’: A Critical Bottleneck in LNP Performance
While PEGylated lipids are essential for the stability and circulation of conventional LNPs, PEG is not biologically inert. It triggers adverse effects that constitute a significant performance bottleneck, a challenge called the “PEG dilemma.” This dilemma results in a trade-off between stability and efficacy. The limitations associated with PEGs severely restrict the safety and efficacy of LNP-based therapeutics, particularly for applications requiring repeated dosing. To address these limitations, researchers have focused on developing novel synthetic strategies for creating advanced polymers that can functionally replace PEG, thereby overcoming this critical performance bottleneck.
In Vitro–In Vivo Correlation (IVIVC) Gap
The IVIVC gap - the persistent failure of simplified lab assays (cytotoxicity, FRET, in vitro transfection) to predict systemic efficacy, biodistribution, and safety - is the core problem that PEG-alternative work must solve. Its root causes and practical implications:
- Oversimplified cell models: immortalized cell lines lack native tissue architecture and the serum environment (immunoglobulins, apolipoproteins), so in vitro results do not transfer to living systems.
- No systemic clearance: in vivo, particles face blood circulation, MPS and protein-corona clearance, biodistribution, and immune activation - none present in a dish - all of which reshape mRNA expression kinetics.
- Divergent optima: the best PEG content differs by setting. ~1.5% DMG-PEG maximized transfection in vitro, whereas ~5% was optimal in vivo; likewise in vitro expression rankings (e.g. SM-102 highest) did not hold in vivo, where ALC-0315 and SM-102 performed comparably.
- Practical implication: in vitro screens alone cannot be trusted to down-select PEG content or stealth-polymer density; a reliable correlation would cut animal testing and de-risk clinical translation.
Synthesis Strategies for Novel PEG-Alternative Lipopolymers
The strategic development of novel polymers with precisely tailored chemical and physical properties is paramount to overcoming the limitations of PEG. Advanced polymer synthesis techniques can be deployed to develop superior alternative hydrophilic polymers or for engineering PEGs to be releasable upon reaching the target site (see below).
1. Developing Alternative “Stealth” Hydrophilic Polymers
These techniques, particularly controlled polymerization methods, are crucial for synthesizing alternative hydrophilic blocks that replicate or surpass PEG’s benefits while mitigating its drawbacks like immunogenicity. See Table 1.
Table 1. Comparison of PEG-Alternative Polymer Classes |
|---|
Polymer Class | Key Advantages & Mechanisms | Synthesis Method & Complexity | Formulation & Stability Challenges |
|---|
Poly(oxazoline)s (POx) - PEtOx, PMOZ | No reaction with anti-PEG antibodies, avoiding the ABC effect; PMOZ-LNPs induce higher virus-neutralizing titers than PEG-LNPs; PEtOx-LNPs internalize within minutes. | High. Cationic ring-opening polymerization (CROP) plus multi-step post-modification (PEtOx-lipid: polymerise → terminate → hydrolyze → succinylate for lipid coupling). | End-group fidelity is critical; dispersity rises with chain length; longer chains lower mRNA encapsulation. |
Polysarcosine (pSar) | Biodegradable polypeptoid; markedly lower anti-polymer IgM/IgG on repeat dosing; reduced cytotoxicity vs PEG. | Controlled polymerization of the endogenous amino acid sarcosine. | Stealth comparable to PEG; long-term immunogenicity still under evaluation. |
Zwitterionic poly(carboxybetaine) (PCB), PyCB | Superhydrophilic; improves endosomal escape and mRNA release; PyCB can replace cholesterol/PEG to redirect LNPs liver → spleen; PCB-LNPs resist the ABC effect across repeat doses. | Moderate. Chemical modification of existing ionizable lipids (e.g. grafting onto ALC-0315) or graft-from RAFT. | Removing cholesterol/PEG needs precise compensation - 0% PyCB formulations disintegrate; >60% zwitterion content blocks cellular uptake. |
Poly(methacrylamides) & RAFT - POEGMA, PHPMA, PDMA | RAFT enables tunable charge (e.g. DMAEMA) that boosts in vivo expression over neutral PEG; higher antigen-specific antibody titers; can be tuned per payload (pDNA vs mRNA). | Moderate. RAFT via a LipoRAFT agent (e.g. ECT-DSG); requires purification to remove RAFT agents. | Structural similarity ≠ function - PHEMA-DSG/PNAM-DSG failed to stabilize LNPs (precipitation); trithiocarbonate end-group may need removal (AIBN); branched POEGMA gives larger particles and lower encapsulation. |
Linear Polyglycerol (lPG) | Biocompatible polyether stealth alternative to PEG. | High. Anionic ring-opening polymerization (AROP) of epoxide monomers with initiators, plus deprotection (debenzylation/acetal removal) to expose hydroxyls. | Short methoxylated variants (MeOlPG) give weak stealth and agglomerate at 4°C; block copolymers (lPG-b-MeOlPG) transfect worse than homopolymers. |
2. Engineering Cleavable or “Sheddable” PEG Coatings
Polymer synthesis techniques can be deployed to introduce stimuli-responsive linkages into the PEG chain or between the PEG chain and the nanoparticle core. This allows the PEG layer to remain intact during circulation (providing stealth) but be removed or “shed” upon reaching the target site (improving efficacy).
- Rationale: The PEG layer provides stealth during long circulation, but also impairs the nanocarriers’ interaction with cells. The strategy of using sheddable PEG groups allows the PEG layer to protect the nanoparticle but sheds after extravasation (leaving the tumor microenvironment) to increase the chance of cellular uptake.
- pH-Responsiveness: PEG can be released through changes in physiological conditions such as pH. For instance, PEG modification can be designed to be hydrolyzed when the pH decreases (to mimic the lower pH in a tumor environment), causing the release of the PEG layer and exposure of a targeting peptide, thereby switching the nanoparticle’s capability from stealth to active uptake.
- Enzyme-Responsiveness: Systems capable of releasing PEG have been designed in response to overexpressed enzymes in tumor environments (e.g., MMP2 and MMP9), by including cleavable peptide sequences (like Pro-Leu-Gly-Leu-Ala-Gly) within the polymer structure.
- Targeting Ligand Integration: PEG’s terminal hydroxyl group can be conjugated with cell-targeting moieties to circumvent the low cellular uptake associated with PEGylation, ensuring specific binding while avoiding steric hindrance.
Formulation and Manufacturing of Next-Generation mRNA-LNPs
The synthesis and polymer chemistry related to LNPs present several specific and difficult challenges for scientists working on formulation and manufacturing. These challenges primarily revolve around the optimization of component structure, particularly the polymeric stealth component, and ensuring reliable, high-quality production methods.
- Challenges in Lipid and Polymer Synthesis (Chemical/Polymer Chemistry): Ionizable lipid design (pKa tuning, tail geometry, and biodegradable ester linkers) is a parallel optimization that is held constant while the stealth polymer is replaced; the synthesis routes and trade-offs of the PEG-alternative lipopolymers themselves are compared below. See Table 2.
- Manufacturing and Quality Control Challenges (Synthesis Methods): Scaling LNP synthesis methods introduces inherent physical and chemical difficulties related to achieving reproducibility and controlling critical quality attributes (CQAs).
Table 2. Manufacturing and Quality Control Challenges in Scaling LNPs |
|---|
Scaling Challenge | Physical/Chemical Difficulty | Impact on CQAs & Mitigation Strategy |
|---|
Throughput Limitations of Microfluidics | Device Physics: Standard Staggered Herringbone Micromixers (SHM) offer precise control but have low throughput (<100 mL/h), creating a bottleneck for clinical supply. Increasing flow rates in single chips often alters the mixing time and Reynolds number, changing particle size. | Impact: High polydispersity (PDI) and inconsistent particle size if scaling is attempted by simply increasing flow rate. Mitigation: Parallelization (Numbering-up): Using devices like Impingement Jet Mixing (IJM) to run many mixers simultaneously (up to 200 mL/min) while maintaining identical mixing physics. |
Sterilization Incompatibility | Thermal & Chemical Instability: LNPs are sensitive to heat and radiation. Autoclaving triggers phase transitions and aggregation, while gamma-irradiation causes lipid oxidation and polymer chain scission. | Impact: Loss of mRNA integrity and changes in LNP morphology (aggregation). Mitigation: Aseptic Processing & Filtration: Manufacturing must be performed under aseptic conditions or utilize mild sterile filtration, though filtration can cause shear stress and deformation. |
Batch-to-Batch Reproducibility | Raw Material Variability: Variations in lipid stocks and mRNA (e.g., dsRNA impurities) can compromise reproducibility. Conventional batch processes often yield large, heterogeneous particles (>100 nm) requiring post-processing (extrusion). | Impact: Inconsistent encapsulation efficiency and PDI > 0.3 (regulatory requirement often < 0.3). Mitigation: Continuous Processing & PAT: Shifting to continuous flow synthesis with Process Analytical Technologies (PAT) for real-time monitoring of particle size and encapsulation. |
It is important to note that, unlike traditional chemical scaling (making a bigger tank), LNP scaling requires “numbering-up” (using hundreds of small mixers in parallel) because the physics of self-assembly relies on rapid mixing at the micro-scale. Pfizer, for instance, used parallelization of impingement jet mixers to reach 100 million doses per month. Also, sterilization is a major hurdle and must not be under-emphasized, because LNPs cannot be terminally sterilized by standard heat/radiation without destroying the supramolecular structure or oxidizing the lipids: The entire manufacturing line must often be aseptic, or rely on filtration which has its own risks (shear stress).
Once formulated, the resulting nanoparticles require rigorous physicochemical characterization to confirm their structural integrity and confirm they meet all critical quality attributes.
Physicochemical Characterization and Quality Control
A comprehensive suite of analytical techniques verifies the critical quality attributes (CQAs) of newly formulated LNPs — particle size, surface charge, and mRNA encapsulation — which directly determine the safety and efficacy of the final product. This section summarizes the characterization data confirming the structural integrity and quality of PEG-alternative LNPs.
Core Quality Attributes: Size, Charge, and Encapsulation
PEG-alternative polymers, when compared to a conventional PEG-LNP control, have been proven to successfully produce nanoparticles with physicochemical characteristics suitable for in vivo delivery:
Table 3. |
|---|
LNP Type | Hydrodynamic Diameter (nm) | Polydispersity Index (PDI) | Zeta Potential (mV) | mRNA Encapsulation Efficiency (%) |
|---|
PEG-LNP (Control) | ~70-100 | < 0.10 | Near-Neutral (-0.15) | > 90% |
PEtOx-LNP | ~140-200 | < 0.15 | Near-Neutral (-2 to -7) | > 80% |
RAFT-LNP (PCB)* | ~100-150 | < 0.15 | Near-Neutral (-15 to -20) | > 85% |
ThrCo-LNP | ~200 | < 0.15 | Not Reported | > 80% |
*RAFT-LNP values are representative of formulations based on SM-102 or ALC-0315 ionizable lipids. |
Verification of Polymer and Lipid Synthesis
The integrity of the novel lipopolymers is a critical quality attribute. To confirm that a synthesis route produced the intended structure, industry-standard QC uses NMR spectroscopy, Size Exclusion Chromatography (SEC), and MALDI-TOF mass spectrometry to verify target molecular weight, low dispersity, and successful end-group modification.
Two impurity classes are decisive CQAs for lipopolymer LNPs. N-oxides in cationic/ionizable lipids and aldehyde impurities both degrade the transcription and translation of the mRNA cargo, directly reducing potency; advanced LC-MS is used to detect and quantify them at trace levels. End-group fidelity and low dispersity of the stealth polymer are confirmed by NMR and SEC. Together, trace N-oxide/aldehyde profiling by LC-MS and end-group/dispersity verification by NMR/SEC gate the release of a PEG-alternative lipopolymer for formulation.
Conclusion and Future Outlook
The synthesis and evaluation of novel polymers have provided highly effective and safer alternatives to PEG in mRNA-LNP formulations, directly confronting the fundamental challenge of the PEG dilemma. This dilemma is the primary bottleneck for advanced nucleic acid therapeutics. Advanced synthesis methodologies, including Cationic Ring-Opening Polymerization (CROP) and Reversible Addition-Fragmentation Chain Transfer (RAFT) polymerization, have enabled a suite of next-generation lipopolymers that replicate PEG’s stabilizing function while successfully mitigating its significant immunogenicity.
While efficacy is proven at laboratory scale, the challenge now pivots to translation. The multi-step synthesis of novel lipids, securing GMP-grade supply, and holding Critical Quality Attributes through commercial scale-up remain the final barriers between validated innovation and clinical reality.
References
- Toward understanding lipid reorganization in RNA lipid nanoparticles in acidic environments Authors: Adiran Garaizara, David Díaz-Oviedoa, Nina Zablowskyc, Sami Rissanend, Johannes Köbberlinga, Jiawei Sune, Christoph Steigere, Patrick Steigemannc, Florian A. Manne, and Katharina Meiera Journal/Publication: PNAS. Published October 30, 2024. DOI: 10.1073/pnas.2404555121
- Replacing poly(ethylene glycol) with RAFT lipopolymers in mRNA lipid nanoparticle systems for effective gene delivery Authors: Dayangku Nordiyana B.P. Hassanel, Emily H. Pilkington, Yi Ju, Stephen J. Kent, Colin W. Pouton, Nghia P. Truong Journal/Publication: International Journal of Pharmaceutics. Volume 665, 15 November 2024, 124695. DOI: 10.1016/j.ijpharm.2024.124695
- Design Strategies for Novel Lipid Nanoparticle for mRNA Vaccine and Therapeutics: Current Understandings and Future Perspectives Authors: Xiaochi Li, Junli Li, Jiazheng Wei, Weixin Du, Cheng Su, Xiaobin Shen, Aihua [Zhao], et al. Journal/Publication: MedComm (2020). 2025 Oct 5;6(10):e70414. DOI: 10.1002/mco2.70414
- Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines Authors: K. Swetha, Niranjan G. Kotla, Lakshmi Tunki, Arya Jayaraj, Suresh K. Bhargava, Haitao Hu, Srinivasa Reddy Bonam, and Rajendra Kurapati Journal/Publication: Vaccines. 2023, 11, 658. DOI: (Not explicitly labeled, but listed in references)
- Source Title: Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development Authors: Meenu Mehta, Thuy Anh Bui, Xinpu Yang, Yagiz Aksoy, Ewa M Goldys, Wei Deng Journal/Publication: ACS Mater Au. 2023 Aug 21;3(6):600–619. DOI: 10.1021/acsmaterialsau.3c00032
- Source Title: Polyglycerol-Based Lipids: A Next-Generation Alternative to PEG in Lipid Nanoparticles for Advanced Drug Delivery Systems Authors: Yara Ensminger, Rashmi Rashmi, Michael Karimov, Gideon Nölte, Markus Hafke, Ann-Cathrin Schmitt, David Díaz-Oviedo, Johannes Köbberling, Rainer Haag, et al. Journal/Publication: Macromolecular Rapid Communications (2025). DOI: (Published Version DOI not explicit, ChemRxiv pre-print cited: 10.26434/chemrxiv-2025-2jf8r-v3)
- Poly(2-methyl-2-oxazoline) as a polyethylene glycol alternative for lipid nanoparticle formulation Authors: Dwain George van Zyl, Livia Palmerston Mendes, Raphaela Patricia Semper, Christine Rueckert, et al. Journal/Publication: Front Drug Deliv. 2024 Apr 26;4:1383038. DOI: 10.3389/fddev.2024.1383038
- Source Title: Poly(carboxybetaine) lipids enhance mRNA therapeutics efficacy and reduce their immunogenicity Authors: Sijin Luozhong, Pingchuan Liu, Ruoxin Li, Zhefan Yuan, Erica Debley, Yu Chen, Yuping Hu, Zeyu Cao, Meng Cui, Kay McIlhenny, Caleb McCurdy, Dani Bhashyam, Stephan Wilkens, Prince Zhang, Austin Kwan, Mark Grossman, Rachel Lai, Yufei Ma, Steven Lipkin, Shaoyi Jiang, et al. Journal/Publication: Nat Mater. 2025 May 29 (Published before final editing). DOI: 10.1038/s41563-025-02240-8
- Source Title: Poly(2-ethyl-2-oxazoline) [POx] as Poly(ethylene glycol) [PEG]-Lipid Substitute for Lipid Nanoparticles (Inferred) Authors: C. T. Holick, T. Klein, C. Mehnert, F. Adermann, I. Anufriev, M. Streiber, A. Traeger, S. Hoeppener, I. Nischang, S. Schubert, U. S. Schubert, et al. Journal/Publication: Small (2025). DOI: 10.1002/smll.202411354
- Source Title: Formulation-Driven Optimization of PEG-Lipid Content in Lipid Nanoparticles for Enhanced mRNA Delivery In Vitro and In Vivo Authors: Wei Liu, Meihui Zhang, Huiyuan Lv and Chuanxu Yang Journal/Publication: Pharmaceutics. 2025, 17, 950. DOI: 10.3390/pharmaceutics17080950
- Source Title: (Untitled Science Advances Article on LNP Delivery/Targeting) Authors: Y. Zhao, Z. Tang, J. Wang, M. Cui, Z. Cao, S. Chen, P. Liu, R. Li, Y. Ma, Y. Hu, et al. Journal/Publication: Science Advances. Published 8 October 2025. DOI: 10.1126/sciadv.ady6460
- Source Title: Exploring the Challenges of Lipid Nanoparticle Development: The In Vitro–In Vivo Correlation Gap Authors: Sarah Lindsay, Muattaz Hussain, Burcu Binici and Yvonne Perrie Journal/Publication: Vaccines. 2025, 13, 339. DOI: 10.3390/vaccines13040339
About the Author
Paul Blundell is the President of Organix, where he has served for over 32 years. Paul specializes in medicinal chemistry and drug discovery, managing preclinical research for both small and large molecules. His technical expertise spans the tropane, lipid, and opioid areas, with a particular interest in imaging agents and polymer synthesis and characterization. Paul’s Ph.D. in Organic Chemistry was conducted under the direct supervision of Nobel laureate Sir Derek Barton. Paul’s research has resulted in 12 patents and over 24 publications.
Rudresha Kottani, Ph.D., is a distinguished synthetic organic chemist with over 24 years of experience spanning academia and the pharmaceutical and chemical industries. He currently serves as Director at Symeres-Organix in Woburn, Massachusetts, USA. His expertise encompasses contemporary synthetic methodologies, complex multi-step synthesis, medicinal chemistry, lipids, polymers, and innovative solutions to challenging synthetic problems. Dr. Kottani has authored numerous publications in leading peer-reviewed journals, including PNAS, JACS, and JOC, and is an inventor on several patents. He is also actively involved in scientific leadership, project management, and mentoring the next generation of chemists.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!